Molecular and synaptic defects in intellectual disability syndromes

Current Opinion in Neurobiology

Volumn 22, Issue 3, 2012, Pages 530-536

  Verpelli, Chiara ^a,b   Sala, Carlo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; MEMBRANE PROTEIN; METHYL CPG BINDING PROTEIN 2; NEUROLIGIN; NEUROLIGIN 3; NEUROLIGIN 4; OLIGOPHRENIN 1; POSTSYNAPTIC DENSITY PROTEIN 95; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SHANK3 PROTEIN; UNCLASSIFIED DRUG;

AUTISM; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q; CYTOSKELETON; DENDRITIC SPINE; DLG4 GENE; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE FUNCTION; GENE MUTATION; HUMAN; ILRAPL1 GENE; INTELLECTUAL IMPAIRMENT; MECP2 GENE; NLGN3 GENE; NLGN4 GENE; NONHUMAN; OLIGOPHRENIN 1 GENE; PATHOGENESIS; PHELAN MCDERMID SYNDROME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RETT SYNDROME; REVIEW; SAP102 GENE; SHANK3 GENE; SYNAPSE; SYNAPTOGENESIS; X CHROMOSOME LINKAGE;

ANIMALS; HUMANS; INTELLECTUAL DISABILITY; MODELS, BIOLOGICAL; MUTATION; SYNAPSES; SYNDROME;

EID: 84863445841     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2011.09.007     Document Type: Review

References (72)

1. Blanpied T.A., Ehlers M.D. Microanatomy of dendritic spines: emerging principles of synaptic pathology in psychiatric and neurological disease. Biol Psychiatry 2004, 55:1121-1127.
2. Rauch A., Hoyer J., Guth S., Zweier C., Kraus C., Becker C., Zenker M., Hüffmeier U., Thiel C., Rüschendorf F., et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006, 140:2063-2074.
3. Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R., Conroy J., Magalhaes T.R., Correia C., Abrahams B.S., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466:368-372.
4. Ropers H.H., Hamel B.C. X-linked mental retardation. Nat Rev Genet 2005, 6:46-57.
5. Jamain S., Quach H., Betancur C., Rastam M., Colineaux C., Gillberg I.C., Soderstrom H., Giros B., Leboyer M., Gillberg C., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003, 34:27-29.
6. Carrie A., Jun L., Bienvenu T., Vinet M.C., McDonell N., Couvert P., Zemni R., Cardona A., Van Buggenhout G., Frints S., et al. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat Genet 1999, 23:25-31.
7. Bhat S.S., Ladd S., Grass F., Spence J.E., Brasington C.K., Simensen R.J., Schwartz C.E., Dupont B.R., Stevenson R.E., Srivastava A.K. Disruption of the IL1RAPL1 gene associated with a pericentromeric inversion of the X chromosome in a patient with mental retardation and autism. Clin Genet 2008, 73:94-96.
8. Franek K.J., Butler J., Johnson J., Simensen R., Friez M.J., Bartel F., Moss T., DuPont B., Berry K., Bauman M., et al. Deletion of the immunoglobulin domain of IL1RAPL1 results in nonsyndromic X-linked intellectual disability associated with behavioral problems and mild dysmorphism. Am J Med Genet A 2011, 155A:1109-1114.
9. Piton A., Michaud J.L., Peng H., Aradhya S., Gauthier J., Mottron L., Champagne N., Lafrenière R.G., Hamdan F.F., Joober R., et al. Mutations in the calcium-related gene IL1RAPL1 are associated with autism. Hum Mol Genet 2008, 17:3965-3974.
10. Bahi N., Friocourt G., Carrie A., Graham M.E., Weiss J.L., Chafey P., Fauchereau F., Burgoyne R.D., Chelly J. IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum Mol Genet 2003, 12:1415-1425.
11. Gambino F., Pavlowsky A., Béglé A., Dupont J.L., Bahi N., Courjaret R., Gardette R., Hadjkacem H., Skala H., Poulain B., et al. IL1-receptor accessory protein-like 1 (IL1RAPL1), a protein involved in cognitive functions, regulates N-type Ca2+-channel and neurite elongation. Proc Natl Acad Sci USA 2007, 104:9063-9068.
12. Pavlowsky A., Gianfelice A., Pallotto M., Zanchi A., Vara H., Khelfaoui M., Valnegri P., Rezai X., Bassani S., Brambilla D., et al. A postsynaptic signaling pathway that may account for the cognitive defect due to IL1RAPL1 mutation. Curr Biol 2010, 20:103-115.
13. Valnegri P, Montrasio C, Brambilla D, Ko JW, Passafaro M, Sala C: The X-linked intellectual disability protein IL1RAPL1 regulates excitatory synapse formation by binding PTPδ and RhoGAP2. Hum Mol Genet 2011, , in press. doi:10.1093/hmg/ddr418.
14. Yoshida T., Yasumura M., Uemura T., Lee S.J., Ra M., Taguchi R., Iwakura Y., Mishina M. IL-1 Receptor Accessory Protein-Like 1 Associated with Mental Retardation and Autism Mediates Synapse Formation by Trans-Synaptic Interaction with Protein Tyrosine Phosphatase {delta}. J Neurosci 2011, 31:13485-13499.
15. Nadif Kasri N., Van Aelst L. Rho-linked genes and neurological disorders. Pflugers Arch 2008, 455:787-797.
16. Govek E.E., Newey S.E., Akerman C.J., Cross J.R., Van der Veken L., Van Aelst L. The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat Neurosci 2004, 7:364-372.
17. Khelfaoui M., Denis C., van Galen E., de Bock F., Schmitt A., Houbron C., Morice E., Giros B., Ramakers G., Fagni L., et al. Loss of X-linked mental retardation gene oligophrenin1 in mice impairs spatial memory and leads to ventricular enlargement and dendritic spine immaturity. J Neurosci 2007, 27:9439-9450.
18. Nadif Kasri N., Nakano-Kobayashi A., Malinow R., Li B., Van Aelst L. The Rho-linked mental retardation protein oligophrenin-1 controls synapse maturation and plasticity by stabilizing AMPA receptors. Genes Dev 2009, 23:1289-1302.
19. Khelfaoui M., Pavlowsky A., Powell A.D., Valnegri P., Cheong K.W., Blandin Y., Passafaro M., Jefferys J.G., Chelly J., Billuart P. Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation. Hum Mol Genet 2009, 18:2575-2583.
20. Valnegri P., Khelfaoui M., Dorseuil O., Bassani S., Lagneaux C., Gianfelice A., Benfante R., Chelly J., Billuart P., Sala C., et al. A circadian clock in hippocampus is regulated by interaction between oligophrenin-1 and Rev-erbα. Nat Neurosci 2011.
21. Bagni C., Greenough W.T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci 2005, 6:376-387.
22. De Rubeis S., Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci 2010, 43:43-50.
23. Bassell G.J., Warren S.T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214.
24. Antar L.N., Li C., Zhang H., Carroll R.C., Bassell G.J. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci 2006, 32:37-48.
25. Antar L.N., Afroz R., Dictenberg J.B., Carroll R.C., Bassell G.J. Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 2004, 24:2648-2655.
26. Ferrari F., Mercaldo V., Piccoli G., Sala C., Cannata S., Achsel T., Bagni C. The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 2007, 34:343-354.
27. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002, 99:7746-7750.
28. Zalfa F., Eleuteri B., Dickson K.S., Mercaldo V., De Rubeis S., di Penta A., Tabolacci E., Chiurazzi P., Neri G., Grant S.G., et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 2007, 10:578-587.
29. Lu R., Wang H., Liang Z., Ku L., O'Donnell W.T., Li W., Warren S.T., Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA 2004, 101:15201-15206.
30. Muddashetty R.S., Kelic S., Gross C., Xu M., Bassell G.J. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 2007, 27:5338-5348.
31. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27:370-377.
32. Napoli I., Mercaldo V., Boyl P.P., Eleuteri B., Zalfa F., De Rubeis S., Di Marino D., Mohr E., Massimi M., Falconi M., et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008, 134:1042-1054.
33. Zalfa F., Giorgi M., Primerano B., Moro A., Di Penta A., Reis S., Oostra B., Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003, 112:317-327.
34. Laggerbauer B., Ostareck D., Keidel E.M., Ostareck-Lederer A., Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 2001, 10:329-338.
35. Li Z., Zhang Y., Ku L., Wilkinson K.D., Warren S.T., Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 2001, 29:2276-2283.
36. Schutt J., Falley K., Richter D., Kreienkamp H.J., Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 2009, 284:25479-25487.
37. Edbauer D., Neilson J.R., Foster K.A., Wang C.F., Seeburg D.P., Batterton M.N., Tada T., Dolan B.M., Sharp P.A., Sheng M. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010, 65:373-384.
38. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19:187-191.
39. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
40. Ricciardi S., Boggio E.M., Grosso S., Lonetti G., Forlani G., Stefanelli G., Calcagno E., Morello N., Landsberger N., Biffo S., et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 2011, 20:1182-1196.
41. Zhou Z., Hong E.J., Cohen S., Zhao W.N., Ho H.Y., Schmidt L., Chen W.G., Lin Y., Savner E., Griffith E.C., et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
42. Chapleau C.A., Calfa G.D., Lane M.C., Albertson A.J., Larimore J.L., Kudo S., Armstrong D.L., Percy A.K., Pozzo-Miller L. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol Dis 2009, 35:219-233.
43. Tropea D., Giacometti E., Wilson N.R., Beard C., McCurry C., Fu D.D., Flannery R., Jaenisch R., Sur M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 2009, 106:2029-2034.
44. Johnston M.V., Blue M.E., Naidu S. Rett syndrome and neuronal development. J Child Neurol 2005, 20:759-763.
45. Li H., Zhong X., Chau K.F., Williams E.C., Chang Q. Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory. Nat Neurosci 2011.
46. Noutel J., Hong Y.K., Leu B., Kang E., Chen C. Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011, 70:35-42.
47. Feyder M., Karlsson R.M., Mathur P., Lyman M., Bock R., Momenan R., Munasinghe J., Scattoni M.L., Ihne J., Camp M., et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome. Am J Psychiatry 2010, 167:1508-1517.
48. Cheng M.C., Lu C.L., Luu S.U., Tsai H.M., Hsu S.H., Chen T.T., Chen C.H. Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia. PLoS ONE 2010, 5:e15107.
49. Tarpey P., Parnau J., Blow M., Woffendin H., Bignell G., Cox C., Cox J., Davies H., Edkins S., Holden S., et al. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet 2004, 75:318-324.
50. Zanni G., van Esch H., Bensalem A., Saillour Y., Poirier K., Castelnau L., Ropers H.H., de Brouwer A.P., Laumonnier F., Fryns J.P., et al. A novel mutation in the DLG3 gene encoding the synapse-associated protein 102 (SAP102) causes non-syndromic mental retardation. Neurogenetics 2010, 11:251-255.
51. Chen B.S., Thomas E.V., Sanz-Clemente A., Roche K.W. NMDA receptor-dependent regulation of dendritic spine morphology by SAP102 splice variants. J Neurosci 2011, 31:89-96.
52. Bonaglia M.C., Giorda R., Borgatti R., Felisari G., Gagliardi C., Selicorni A., Zuffardi O. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 2001, 69:261-268.
53. Phelan M.C., Rogers R.C., Saul R.A., Stapleton G.A., Sweet K., McDermid H., Shaw S.R., Claytor J., Willis J., Kelly D.P. 22q13 deletion syndrome. Am J Med Genet 2001, 101:91-99.
54. Wilson H.L., Wong A.C., Shaw S.R., Tse W.Y., Stapleton G.A., Phelan M.C., Hu S., Marshall J., McDermid H.E. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003, 40:575-584.
55. Manning M.A., Cassidy S.B., Clericuzio C., Cherry A.M., Schwartz S., Hudgins L., Enns G.M., Hoyme H.E. Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 2004, 114:451-457.
56. Delahaye A., Toutain A., Aboura A., Dupont C., Tabet A.C., Benzacken B., Elion J., Verloes A., Pipiras E., Drunat S. Chromosome 22q13.3 deletion syndrome with a de novo interstitial 22q13.3 cryptic deletion disrupting SHANK3. Eur J Med Genet 2009, 52:328-332.
57. Durand C.M., Betancur C., Boeckers T.M., Bockmann J., Chaste P., Fauchereau F., Nygren G., Rastam M., Gillberg I.C., Anckarsater H., et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007, 39:25-27.
58. Moessner R., Marshall C.R., Sutcliffe J.S., Skaug J., Pinto D., Vincent J., Zwaigenbaum L., Fernandez B., Roberts W., Szatmari P., et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007, 81:1289-1297.
59. Gauthier J., Spiegelman D., Piton A., Lafreniere R.G., Laurent S., St-Onge J., Lapointe L., Hamdan F.F., Cossette P., Mottron L., et al. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:421-424.
60. Berkel S., Marshall C.R., Weiss B., Howe J., Roeth R., Moog U., Endris V., Roberts W., Szatmari P., Pinto D., et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 2010, 42:489-491.
61. Hung A.Y., Futai K., Sala C., Valtschanoff J.G., Ryu J., Woodworth M.A., Kidd F.L., Sung C.C., Miyakawa T., Bear M.F., et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 2008, 28:1697-1708.
62. Wöhr M., Roullet F.I., Hung A.Y., Sheng M., Crawley J.N. Communication impairments in mice lacking Shank1: reduced levels of ultrasonic vocalizations and scent marking behavior. PLoS ONE 2011, 6:e20631.
63. Bangash M.A., Park J.M., Melnikova T., Wang D., Jeon S.K., Lee D., Syeda S., Kim J., Kouser M., Schwartz J., et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 2011, 145:758-772.
64. Bozdagi O., Sakurai T., Papapetrou D., Wang X., Dickstein D.L., Takahashi N., Kajiwara Y., Yang M., Katz A.M., Scattoni M.L., et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 2010, 1:15.
65. Peça J., Feliciano C., Ting J.T., Wang W., Wells M.F., Venkatraman T.N., Lascola C.D., Fu Z., Feng G. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011.
66. Wang X., McCoy P.A., Rodriguiz R.M., Pan Y., Je H.S., Roberts A.C., Kim C.J., Berrios J., Colvin J.S., Bousquet-Moore D., et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011.
67. Verpelli C., Dvoretskova E., Vicidomini C., Rossi F., Chiappalone M., Schoen M., Di Stefano B., Mantegazza R., Broccoli V., Boeckers T.M., et al. Importance of shank3 in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem 2011.
68. Hamdan F.F., Gauthier J., Araki Y., Lin D.T., Yoshizawa Y., Higashi K., Park A.R., Spiegelman D., Dobrzeniecka S., Piton A., et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 2011, 88:306-316.
69. Jourdi H., Hsu Y.T., Zhou M., Qin Q., Bi X., Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci 2009, 29:8688-8697.
70. Sale A., Maya Vetencourt J.F., Medini P., Cenni M.C., Baroncelli L., De Pasquale R., Maffei L. Environmental enrichment in adulthood promotes amblyopia recovery through a reduction of intracortical inhibition. Nat Neurosci 2007, 10:679-681.
71. Lonetti G., Angelucci A., Morando L., Boggio E.M., Giustetto M., Pizzorusso T. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol Psychiatry 2010, 67:657-665.
72. Marchetto M.C., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., Chen G., Gage F.H., Muotri A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.